An overview of the recent findings of cell-based therapies for the treatment and management of COVID-19

Ghaffari, Sasan; Kazerooni, Hanif; Salehi-Najafabadi, Amir

doi:10.1016/j.intimp.2021.108226

Cited by 1 publication

(1 citation statement)

References 98 publications

(85 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 149 CAR-NK cell consists of isolating NK cells and modify these cells to express CAR that targets a tumor-specific protein for instance and then re-infuse them back into the recipient. 150 , 151 CAR-modified human pluripotent stem cells might hold the capacity to produce functional CAR NK cells continuously, a potential solution to deal with the relative shorter life span of NK cells. 152 Although NK92 cell line is often considered for application in NK cell therapy based clinical trials, they have to be irradiated due to the reason they are aneuploid.…”

Section: Methodsmentioning

confidence: 99%

Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?

Zeng

2022

DDDT

View full text Add to dashboard Cite

The COVID-19 has plunged the world into a pandemic that affected millions. The continually emerging new variants of concern raise the question as to whether the existing vaccines will continue to provide sufficient protection for individuals from SARS-CoV-2 during natural infection. This narrative review aims to briefly outline various immunotherapeutic options and discuss the potential of clustered regularly interspaced short palindromic repeat (CRISPR Cas system technology against COVID-19 treatment as specific cure. As the development of vaccine, convalescent plasma, neutralizing antibodies are based on the understanding of human immune responses against SARS-CoV-2, boosting human body immune responses in case of SARS-CoV-2 infection, immunotherapeutics seem feasible as specific cure against COVID-19 if the present challenges are overcome. In cell based therapeutics, apart from the high costs, risks and side effects, there are technical problems such as the production of sufficient potent immune cells and antibodies under limited time to treat the COVID-19 patients in mild conditions prior to progression into a more severe case. The CRISPR Cas technology could be utilized to refine the specificity and safety of CAR-T cells, CAR-NK cells and neutralizing antibodies against SARS-CoV-2 during various stages of the COVID-19 disease progression in infected individuals. Moreover, CRISPR Cas technology are proposed in hypotheses to degrade the viral RNA in order to terminate the infection caused by SARS-CoV-2. Thus personalized cocktails of immunotherapeutics and CRISPR Cas systems against COVID-19 as a strategy might prevent further disease progression and circumvent immunity escape.

show abstract

Section: Methodsmentioning

confidence: 99%

Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?

Zeng

2022

DDDT

View full text Add to dashboard Cite

show abstract

An overview of the recent findings of cell-based therapies for the treatment and management of COVID-19

Cited by 1 publication

References 98 publications

Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?

Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?

Contact Info

Product

Resources

About